Abstract
Human papilloma virus (HPV)-associated oropharyngeal carcinoma (HPV-OPC) is increasing in many countries. It has distinct microscopic and molecular features as well as clinical aspects. As for microscopic view, two subtypes, non-keratinizing squamous cell carcinoma (NKSCC) and hybrid SCC (HSCC), 3 variants of SCC, undifferentiated carcinoma (UC), basaloid carcinoma (BC), and papillary squamous cell carcinoma (PSCC), and 2 histological structures, abrupt keratinizarion and comedo-necrosis among non-maturing island are related with HPV-OPC. As for molecular aspects, HPV-OPC is more likely to have p53 degradation and Rb (retinoblastoma protein) inactivation with resulting p16 up-regulation compared to HPV-unassociated oropharyngeal carcinoma.
Keywords: Detection method, HPV-associated oropharyngeal carcinoma pathological diagnosis, Human papillomavirus (HPV), molecular diagnosis.
Current Cancer Therapy Reviews
Title:Pathology of the HPV-associated Oropharyngeal Carcinoma
Volume: 11 Issue: 1
Author(s): Yuki Fukumura
Affiliation:
Keywords: Detection method, HPV-associated oropharyngeal carcinoma pathological diagnosis, Human papillomavirus (HPV), molecular diagnosis.
Abstract: Human papilloma virus (HPV)-associated oropharyngeal carcinoma (HPV-OPC) is increasing in many countries. It has distinct microscopic and molecular features as well as clinical aspects. As for microscopic view, two subtypes, non-keratinizing squamous cell carcinoma (NKSCC) and hybrid SCC (HSCC), 3 variants of SCC, undifferentiated carcinoma (UC), basaloid carcinoma (BC), and papillary squamous cell carcinoma (PSCC), and 2 histological structures, abrupt keratinizarion and comedo-necrosis among non-maturing island are related with HPV-OPC. As for molecular aspects, HPV-OPC is more likely to have p53 degradation and Rb (retinoblastoma protein) inactivation with resulting p16 up-regulation compared to HPV-unassociated oropharyngeal carcinoma.
Export Options
About this article
Cite this article as:
Fukumura Yuki, Pathology of the HPV-associated Oropharyngeal Carcinoma, Current Cancer Therapy Reviews 2015; 11 (1) . https://dx.doi.org/10.2174/1573394711666150428003428
DOI https://dx.doi.org/10.2174/1573394711666150428003428 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition Epigenetics in Ocular Diseases
Current Genomics CDK5 and MAPT Gene Expression in Alzheimer's Disease Brain Samples
Current Alzheimer Research Dietary Polyphenols for Prostate Cancer Therapy
Current Bioactive Compounds Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs Chemosensitization by Antisense Oligonucleotides Targeting MDM2
Current Cancer Drug Targets Epithelial Mesenchymal Transition in Cancer Progression: Prev entive Phytochemicals
Recent Patents on Anti-Cancer Drug Discovery Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry The Role and Predictive Value of Cytokines in Atherosclerosis and Coronary Artery Disease
Current Medicinal Chemistry The mRNA-HPV Test Utilization in the Follow Up of HPV Related Cervical Lesions
Current Pharmaceutical Design CYP24A1 as a Potential Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Phosphopeptides - Chemical Synthesis, Analysis, Outlook and Limitations.
Current Organic Chemistry Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis
Current Stem Cell Research & Therapy From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets The Chemometric Evaluation of Antitumor Activity of Novel Benzensulfonamide Derivatives Based on their Physiochemical Properties
Letters in Drug Design & Discovery Bisacylimidoselenocarbamates Cause G2/M Arrest Associated with the Modulation of CDK1 and Chk2 in Human Breast Cancer MCF-7 Cells
Current Medicinal Chemistry Matrine: Bioactivities and Structural Modifications
Current Topics in Medicinal Chemistry